TABLE 1.

Susceptibility of biofilm-associated C. albicans cells from clinical isolates to antimicrobials

Antimicrobial	50% RMA (μg/ml)a	50% RS (μg/ml)b
Voriconazole	64	32
Fluconazole	64	64
NO-np	5,000 (5.64 × 10−6c; 3.76 × 10−6d,e)	5,000 (5.64 × 10−6c; 3.76 × 10−6d,e)

^a50% RMA, a 50% reduction in metabolic activity, as determined by the XTT reduction assay.

^b50% RS, a 50% reduction in survival, as determined by the CFU killing assay.

^cActual nitric oxide in solution for initial peak.

^dActual nitric oxide in solution for steady state.

^eP < 0.05.